+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Critical Limb Ischemia Treatment Market by Treatment Type (Angioplasty & Stenting, Endarterectomy, Hyperbaric Oxygen Therapy), End-Use (Home Health Care, Hospitals, Outpatient Surgical Centers) - Forecast 2024-2030- Product Image
Global Critical Limb Ischemia Treatment Market by Treatment Type (Angioplasty & Stenting, Endarterectomy, Hyperbaric Oxygen Therapy), End-Use (Home Health Care, Hospitals, Outpatient Surgical Centers) - Forecast 2024-2030- Product Image
Sale

Global Critical Limb Ischemia Treatment Market by Treatment Type (Angioplasty & Stenting, Endarterectomy, Hyperbaric Oxygen Therapy), End-Use (Home Health Care, Hospitals, Outpatient Surgical Centers) - Forecast 2024-2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967998
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Critical Limb Ischemia Treatment Market size was estimated at USD 4.11 billion in 2023, USD 4.46 billion in 2024, and is expected to grow at a CAGR of 8.84% to reach USD 7.45 billion by 2030.

Critical limb ischemia (CLI) treatment encompasses therapeutic strategies aimed at restoring sufficient blood flow to the limbs, specifically the legs, to alleviate the severe pain and to prevent potential limb loss associated with the advanced stage of peripheral arterial disease (PAD). The treatment spectrum includes a range of options from minimally invasive procedures including angioplasty and stent placement to more complex surgical interventions such as bypass surgery, along with the administration of medications to improve blood flow and procedures to address wound care and limb salvage.

The expanding use of these treatments is majorly attributed to the growing incidences of diabetes, obesity, and other lifestyle-related diseases that heighten the risk of developing PAD, coupled with advancements in medical technologies that improve the efficacy & safety of treatment procedures. However, the risk of procedural complications, the potential need for multiple surgeries, and the high costs associated with advanced treatment modalities may challenge the market growth. Nevertheless, the development and adoption of personalized medicine approaches, leveraging advancements in genomics and biotechnology to tailor treatments to individual patients, is expected to provide added growth for market expansion.

Regional Insights

In the Americas, particularly the United States and Canada, the CLI treatment market is characterized by advanced healthcare infrastructure & high adoption rate of innovative treatments. The region emphasizes minimally invasive surgeries, angioplasty, or bypass surgery, based on the severity of the condition. There is an increasing preference for endovascular treatments due to their less invasive nature and shorter recovery times. Furthermore, the availability and insurance coverage for these procedures significantly influence treatment accessibility and choice. The EMEA region presents a fragmented market due to varying healthcare policies, economic statuses, and access to healthcare facilities.

Western European countries, with their robust healthcare systems, closely follow the Americas in adopting advanced treatments and technologies for CLI. There is a strong emphasis on research and development, exploring innovative solutions such as gene therapy and regenerative medicine. The Asia Pacific region is diverse in its economic development and healthcare systems, leading to varied approaches to CLI treatment. Countries such as Japan, Australia, and Singapore are at the forefront, utilizing cutting-edge technologies and treatments similar to those in the Americas and Western Europe. However, in less developed parts of Asia, affordability and access to healthcare services remain significant barriers.

Market Trends by Segment

  • Treatment Type: Adoption of angioplasty and stenting as minimally invasive procedures
  • End-Use: Importance of hospitals in the diagnosis, treatment, and emergency care of CLI patients

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Advanced Treatment for Critical Limb-Threatening Ischemia with Abbott's Esprit BTK System

Abbott has revealed compelling results from the LIFE-BTK clinical trial, showcasing the effectiveness of the Esprit BTK Everolimus Eluting Resorbable Scaffold System for treating individuals suffering from chronic limb-threatening ischemia (CLTI). The Esprit BTK system distinguishes itself by being a drug-eluting resorbable scaffold designed to temporarily support reopened vessels in the lower extremities, unlike permanent metal stents, addressing a significant unmet medical need in the United States where no such approved options exist for below-the-knee interventions.

LimFlow System Offers New Hope for Severe Peripheral Artery Disease Patients Facing Amputation

The U.S. Food & Drug Administration (FDA) has recently approved the LimFlow System, a groundbreaking technology developed by LimFlow SA. This innovative system presents a life-changing solution for patients suffering from a severe form of peripheral artery disease (PAD) who have exhausted all other treatment avenues and are on the brink of major limb amputation. The Transcatheter Arterialization of Deep Veins (TADV) technique employed by the LimFlow System aims to restore blood flow in patients' deep veins, thereby offering a chance to save the affected limbs.

Key Company Profiles

The report delves into recent significant developments in the Critical Limb Ischemia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambulero Inc, Amgen Inc., Antidote Therapeutics Inc, Athersys Inc, Boston Scientific Corporation, Caladrius Biosciences Inc, Cardiovascular Systems, Inc., Cesca Therapeutics Inc., Constant Therapeutics LLC, Cynata Therapeutics Ltd, Eli Lilly and Company, Gurus BioPharm Inc, Helixmith Co Ltd, Hemostemix Inc, ID Pharma Co Ltd, ImmuneCyte Inc, Ixaka Ltd, LimFlow SA, Lisata Therapeutics, Medtronic plc, Micro Medical Solutions, Novartis AG, Pluristem Therapeutics Inc., Rexgenero Ltd., Sanofi S.A., Stempeutics Research Pvt Ltd., and Teva Pharmaceutical Industries Ltd.

This research report offers invaluable insights into various crucial aspects of the Critical Limb Ischemia Treatment Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of diabetes and obesity
5.1.1.2. Innovations in minimally invasive procedures and regenerative medicine
5.1.1.3. Increased patient and clinician awareness about early diagnosis and treatment options
5.1.2. Restraints
5.1.2.1. Risk of procedural complications
5.1.3. Opportunities
5.1.3.1. Innovations in stem cell therapy and gene therapy
5.1.3.2. Advances in robotic surgery and hybrid operating rooms
5.1.4. Challenges
5.1.4.1. High costs associated with advanced treatment modalities
5.2. Market Segmentation Analysis
5.2.1. Treatment Type: Adoption of angioplasty and stenting as minimally invasive procedures
5.2.2. End-Use: Importance of hospitals in the diagnosis, treatment, and emergency care of CLI patients
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Critical Limb Ischemia Treatment Market, by Treatment Type
6.1. Introduction
6.2. Angioplasty & Stenting
6.3. Endarterectomy
6.4. Hyperbaric Oxygen Therapy
6.5. Medication
6.6. Surgical Bypass
7. Critical Limb Ischemia Treatment Market, by End-Use
7.1. Introduction
7.2. Home Health Care
7.3. Hospitals
7.4. Outpatient Surgical Centers
7.5. Specialized Vascular Clinics
7.6. Wound Care Centers
8. Americas Critical Limb Ischemia Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Critical Limb Ischemia Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Critical Limb Ischemia Treatment Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. Advanced Treatment for Critical Limb-Threatening Ischemia with Abbott's Esprit BTK System
11.3.2. LimFlow System Offers New Hope for Severe Peripheral Artery Disease Patients Facing Amputation
11.4. Strategy Analysis & Recommendation
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
List of Figures
FIGURE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CRITICAL LIMB ISCHEMIA TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY & STENTING, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY & STENTING, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL BYPASS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL BYPASS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOME HEALTH CARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOME HEALTH CARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY OUTPATIENT SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY OUTPATIENT SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALIZED VASCULAR CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALIZED VASCULAR CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 37. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 38. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 39. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 40. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 41. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 42. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 43. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 44. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 45. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 46. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 47. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 48. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 49. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 50. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 51. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 52. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 53. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 54. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 55. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 56. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 57. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 58. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 60. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 62. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 64. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 65. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 66. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 67. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 68. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 69. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 70. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 71. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 72. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 73. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 74. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 75. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 76. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 77. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 78. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 79. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 80. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 81. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 82. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 83. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 84. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 85. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 86. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 87. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 88. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 89. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 90. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 91. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 92. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 93. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 94. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 95. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 96. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 97. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 98. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 99. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 100. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 101. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 102. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 103. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 104. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 105. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 106. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 107. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 108. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 109. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 110. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 111. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 112. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 119. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 120. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 121. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 122. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 123. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 124. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 125. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 126. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 127. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 128. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 129. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 130. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 131. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 132. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 133. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 134. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 135. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 136. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 137. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 138. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 139. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 140. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 141. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 142. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 143. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 144. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 145. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 146. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 147. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 148. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 149. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 150. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 151. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 152. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 153. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 154. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 155. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 156. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 157. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 158. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 159. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 160. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 161. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 162. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 163. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 164. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 165. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 166. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 167. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 168. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 169. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 170. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 172. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 174. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 176. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 178. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 179. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 180. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 181. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 182. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 183. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 184. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 185. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 186. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 187. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 188. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 189. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 190. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 191. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 192. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 193. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 194. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
TABLE 200. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 202. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 203. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 204. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • Abbott Laboratories
  • Ambulero Inc
  • Amgen Inc.
  • Antidote Therapeutics Inc
  • Athersys Inc
  • Boston Scientific Corporation
  • Caladrius Biosciences Inc
  • Cardiovascular Systems, Inc.
  • Cesca Therapeutics Inc.
  • Constant Therapeutics LLC
  • Cynata Therapeutics Ltd
  • Eli Lilly and Company
  • Gurus BioPharm Inc
  • Helixmith Co Ltd
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • ImmuneCyte Inc
  • Ixaka Ltd
  • LimFlow SA
  • Lisata Therapeutics
  • Medtronic plc
  • Micro Medical Solutions
  • Novartis AG
  • Pluristem Therapeutics Inc.
  • Rexgenero Ltd.
  • Sanofi S.A.
  • Stempeutics Research Pvt Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.46 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.45 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Critical Limb Ischemia Global Market Report 2024 - Product Image

Critical Limb Ischemia Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Critical Limb Ischemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Critical Limb Ischemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 136 Pages
  • Global
From
Critical Limb Ischemia - Pipeline Insight, 2024 - Product Image

Critical Limb Ischemia - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
LSTA-12 Market Size, Forecast, and Emerging Insight - 2032 - Product Image

LSTA-12 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • 30 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.